Damora Therapeutics (DMRA) Cash & Equivalents (2019 - 2026)

Damora Therapeutics (DMRA) has 8 years of Cash & Equivalents data on file, last reported at $202.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 1595.25% year-over-year to $202.4 million; the trailing twelve-month figure through Mar 2026 stood at $202.4 million (up 1595.25% YoY), and the FY2025 full-year result was $257.6 million, up 1717.45% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $202.4 million, down from $257.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $257.6 million in Q4 2025 and bottomed at $7.6 million in Q3 2025.
• The 5-year median for Cash & Equivalents is $25.1 million (2023), against an average of $47.2 million.
• The widest annual swing landed in 2024, when Cash & Equivalents slumped 77.83%; it then jumped 1717.45% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $32.8 million in 2022, then declined by 22.85% to $25.3 million in 2023, then tumbled by 43.96% to $14.2 million in 2024, then surged by 1717.45% to $257.6 million in 2025, then fell by 21.44% to $202.4 million in 2026.
• The last three Cash & Equivalents figures came in at $202.4 million (Q1 2026), $257.6 million (Q4 2025), and $7.6 million (Q3 2025), per Business Quant data.

Peer Comparison